![Ji Zheng Chen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ji Zheng Chen
Direttore/Membro del Consiglio presso SINOCARE INC.
Posizioni attive di Ji Zheng Chen
Società | Posizione | Inizio | Fine |
---|---|---|---|
SINOCARE INC. | Direttore/Membro del Consiglio | 31/08/2023 | - |
Independent Dir/Board Member | 31/08/2023 | - | |
Denovo Biopharma Co., Ltd.
![]() Denovo Biopharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Denovo Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company based in Beijing, China. Denovo Biopharma uses novel biomarker approaches to execute efficient clinical trials in targeted patient populations to optimize the probability of successful trials. The Chinese company has eight late clinical stage drugs in its pipeline addressing major unmet medical needs in oncology and CNS diseases, most of which are first-in-class drugs with rights. Denovo Biopharma seeks to discover genomic biomarkers correlated with patients' responses to drug candidates retrospectively. The company designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo Biopharma is enrolling patients in a phase 3 clinical trial for its lead asset db102 (enzastaurin) in diffuse large B-cell lymphoma (DLBCL) and will start a phase 2b study in glioblastoma (GBM). The company has four additional late-stage programs targeting major unmet needs\: db103 for schizophrenia, db104 for depression, db105 for Alzheimer's disease, and db106 for acute myeloid leukemia (AML). Denovo Biopharma is a next-generation biomarker partner to personalize your drug. The company was founded in 2012 by Wen Luo. | Direttore/Membro del Consiglio | - | - |
Direttore Finanziario/CFO | - | - | |
Segretario Aziendale | - | - |
Storia della carriera di Ji Zheng Chen
Formazione di Ji Zheng Chen
National Chengchi University | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistiche
Distribuzione geografica
Cina | 3 |
Taiwan | 2 |
Stati Uniti | 2 |
Posizioni
Director/Board Member | 2 |
Director of Finance/CFO | 1 |
Corporate Secretary | 1 |
Settori
Health Technology | 3 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
SINOCARE INC. | Health Technology |
Aziende private | 1 |
---|---|
Denovo Biopharma Co., Ltd.
![]() Denovo Biopharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Denovo Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company based in Beijing, China. Denovo Biopharma uses novel biomarker approaches to execute efficient clinical trials in targeted patient populations to optimize the probability of successful trials. The Chinese company has eight late clinical stage drugs in its pipeline addressing major unmet medical needs in oncology and CNS diseases, most of which are first-in-class drugs with rights. Denovo Biopharma seeks to discover genomic biomarkers correlated with patients' responses to drug candidates retrospectively. The company designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo Biopharma is enrolling patients in a phase 3 clinical trial for its lead asset db102 (enzastaurin) in diffuse large B-cell lymphoma (DLBCL) and will start a phase 2b study in glioblastoma (GBM). The company has four additional late-stage programs targeting major unmet needs\: db103 for schizophrenia, db104 for depression, db105 for Alzheimer's disease, and db106 for acute myeloid leukemia (AML). Denovo Biopharma is a next-generation biomarker partner to personalize your drug. The company was founded in 2012 by Wen Luo. | Health Technology |
- Borsa valori
- Insiders
- Ji Zheng Chen
- Esperienza